Virus News and Research

Latest Virus News and Research

Ebola research: an interview with Professor Easton, University of Warwick

Ebola virus belongs to a group of viruses that have been known for some time. It was first isolated as a result of an infection in a primate, in a monkey colony, in monkeys that were being used for research in the Philippines.

28 May 2014

Contemporary dataset reveals burden of paediatric pneumococcal disease

Children with chronic or immunocompromising medical conditions continue to be at increased risk for developing pneumococcal disease in the current era of universal immunisation, US researchers report.

28 May 2014

Researchers develop new technology that uses HIV virus as tool to fight against hereditary diseases

For the first time researchers have succeeded in altering HIV virus particles so that they can simultaneously, as it were, 'cut and paste' in our genome via biological processes. Developed at the Department of Biomedicine at Aarhus University, the technology makes it possible to repair genomes in a new way.

28 May 2014

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Inovio Pharmaceuticals, Inc. announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge.

27 May 2014

Longer looks: How doctors treat patients; myths about Obamacare; curing cancer

Many years ago I spent a lunch hour in a doctors' dining room eavesdropping on two white-coated men of a certain age idly discussing a colleague who worked at the city hospital next door.

23 May 2014

Study: Children born with HIV more likely to develop resistance to antiretroviral drugs than adults

Children born with HIV are far more likely to develop resistance to antiretroviral drugs than adults, according to a new Tulane University School of Medicine study.

23 May 2014

Study: RNAi silencing strategy blocks production of mutant huntingtin protein

A targeted gene silencing strategy blocks production of the dysfunctional huntingtin (Htt) protein, the cause of Huntington's disease, a fatal, inherited neurodegenerative disorder.

22 May 2014

Novel scrapbook-inspired test helps patients diagnosed with hepatitis C

To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way.

22 May 2014

Researchers identify existing drugs that could be "repurposed" to fight MERS-CoV

A team led by a University of Maryland School of Medicine (UM SOM) researcher, working as a grantee from the National Institutes of Health (NIH), has identified a number of existing drugs that could be "repurposed" to fight outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).

22 May 2014

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age.

22 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

Three scientists selected to receive NIDA's 2014 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from enhancing the immune system's ability to fight HIV infection to improving long-term immune health in HIV-infected drug users, three scientists have been chosen to receive the 2014 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health.

19 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

IAVI: Together, we can achieve a world without AIDS

Do you remember the world before HIV/AIDS? Where will you be when the shadow of this disease is finally gone?

19 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Chronic bystander viral impairs development of memory T cells

Studies of vaccine programs in the developing world have revealed that individuals with chronic infections such as malaria and hepatitis tend to be less likely to develop the fullest possible immunity benefits from vaccines for unrelated illnesses.

16 May 2014

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus—thanks to the diversity of targets the site presents to the human immune system.

16 May 2014

U.S. urges daily pill for those at risk of AIDS

The recommendation could transform AIDS prevention from reliance on condoms to a regimen that relies on an antiretroviral drug. Meanwhile, a report analyzes the costs and benefits of treating prison inmates for hepatitis C and a study finds that nearly half of American adults take prescriptions.

16 May 2014

Virus News and Research

Latest Virus News and Research

Ebola research: an interview with Professor Easton, University of Warwick

Contemporary dataset reveals burden of paediatric pneumococcal disease

Researchers develop new technology that uses HIV virus as tool to fight against hereditary diseases

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Longer looks: How doctors treat patients; myths about Obamacare; curing cancer

Study: Children born with HIV more likely to develop resistance to antiretroviral drugs than adults

Study: RNAi silencing strategy blocks production of mutant huntingtin protein

Novel scrapbook-inspired test helps patients diagnosed with hepatitis C

Researchers identify existing drugs that could be "repurposed" to fight MERS-CoV

Dolutegravir drug offers added benefit in HIV patients

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Existing pharmaceutical drugs may offer effective therapies against MERS

Three scientists selected to receive NIDA's 2014 Avant-Garde Award for HIV/AIDS Research

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

IAVI: Together, we can achieve a world without AIDS

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Chronic bystander viral impairs development of memory T cells

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

U.S. urges daily pill for those at risk of AIDS

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Virus News and Research

Latest Virus News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in